Duration of clinically meaningful improvement in pain as a patient-centered endpoint in acute pain trials [0.03%]
急性疼痛临床试验中具有临床意义的镇痛持续时间作为以患者为中心的主要评价指标
Christopher J Miller,Ian DeLorey,Warren B Bilker et al.
Christopher J Miller et al.
Current US Food and Drug Administration (FDA) guidance recommends the sum of pain intensity differences (SPID) as the primary efficacy endpoint for acute pain trials, which lacks validated thresholds for clinically meaningful change and req...
Mark Daniel Sullivan,Amanda C de C Williams
Mark Daniel Sullivan
Pain, suffering, and the limits of conceptual unification: a comment on Sullivan and Williams [0.03%]
痛苦、苦难和概念统一的限度：评论桑普森和威廉斯的文章
Niklas Noe-Steinmüller,Jonas Tesarz
Niklas Noe-Steinmüller
Reply to Peng and Chen [0.03%]
回复彭亚和陈平的文章
Chien-Ying Lee
Chien-Ying Lee
Revisiting fracture risk with pregabalin: selection bias and the challenge of causal inference [0.03%]
从加巴喷平的风险再看骨折：选择偏差及因果推断的挑战
Xi-Yuan Peng,Hong-Lin Chen
Xi-Yuan Peng
Response to Plaut [0.03%]
对普洛特的回应
Natasha L Orr,Paul J Yong
Natasha L Orr
Reply to "Defining the boundary between pain and suffering" by Cohen, Quintner and Weisman [0.03%]
对Cohen、Quintner和Weisman关于“界定疼痛与苦难边界”的回复
Mark D Sullivan,Amanda C de C Williams
Mark D Sullivan
Milton L Cohen,John L Quintner,Asaf K Weisman
Milton L Cohen